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ABSTRACT 
Growing enthusiasm around machine perfusion (MP) in clinical liver transplantation (LT) 
may be the preamble for standardized practice to expand the donors' pool. The present 
systematic review investigated all the liver transplantations performed using grafts treated 
with MP. A systematic review of 309 papers was performed. Eventually, 27 articles were 
enrolled for the study. A total number of 173 cases was reported. Only 12 cohort studies were 
identified: the remaining ones were case reports or case series. Hypothermic machine 
perfusion was performed in 102 (59.0%), normothermic machine perfusion in 65 (37.6%), 
and controlled oxygenated rewarming in the remaining 6 (3.4%) cases. Donor characteristics, 
evaluation of graft quality and end-points were not homogeneous among the studies. Overall, 
post-LT results were excellent, with 1.2 and 4.0% of patients experienced primary non-
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function and ischemic-type biliary lesions, respectively. Conclusion: no study exists that 
address the role of MP in selecting liver grafts available for LT. All the published studies 
mainly focused on the feasibility and safety of this new technology. Further research 
investigating the selection process of marginal donors is required. 
 
 
INTRODUCTION 
Improvement in ex vivo liver preservation represents one of the main goals in the setting of 
clinical liver transplantation (LT), aiming at increasing the number of grafts to transplant and 
improving their quality at the same time. 
Simple cold storage [1]  has been the mainstay in clinical practice since Geoffrey Collins 
introduced it in 1969. [2] However, the growing gap between the number of available organs 
and that of patients awaiting transplants, forced the scientific community to seek new 
solutions to reduce the waiting list deaths. [3] A more liberal use of the so-called “extended 
criteria” organs has been proposed in recent times, with the intent of increasing organs for 
transplantation. This sub-group of grafts includes a miscellaneous of different conditions with 
the common denominator of being more vulnerable to ischemia, hence carrying an increased 
risk of post-LT graft dysfunction. [4] Among them, we can surely include donors after 
cardiac death (DCD), [5] severely steatotic grafts, [6] organs from elderly donors, [7] and 
livers with a prolonged cold ischemia time (i.e., >12 hours). [8] 
Machine perfusion (MP) might represent a way around for utilizing sub-optimal resources 
minimizing the risk of poor graft function. Initially introduced in the clinical practice for 
preserving “marginal” kidneys for transplantation, [9] the concept of MP has been 
progressively translated in the LT setting. After several experimental studies on animal 
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models [10-12] and discarded human livers, [13-15] the first clinical series using MP was 
eventually reported by Guarrera et al. in 2010. [16]  
Since then, multiple experiences have been reported worldwide, fostering high expectations 
concerning the following implementation of MPs into clinical practice. [11,17-41] However, 
several obstacles, as the necessity of finding objective MP-related variables to select grafts 
suitable for LT, still stand.        
From this standpoint, a qualitative systematic review was done, identifying all the clinical 
liver transplants performed using MP grafts. When available, MP-related selective criteria of 
graft quality and outcome were specifically investigated.  
MATERIALS AND METHODS 
Search strategy 
A systematic search was done about relevant studies focusing on the use of MP in the setting 
of clinical LT. The search strategy complied with the Preferred Reporting Items for Systemic 
Reviews and Meta-Analysis (PRISMA) guidelines, as well as PRISMA for abstracts. [42] A 
search of the electronic databases MEDLINE-PubMed and Cochrane Library was conducted 
using the following search terms: perfusion machine AND liver transplantation. Studies 
published before November 30, 2017, were considered.  
Screening process 
The present qualitative systematic review included a priori search criteria of journal articles 
among adult (age ≥18 years) human LT recipients. Studies were limited to the English 
language.  
Exclusion criteria were studies lacking sufficient statistical details as well as review articles, 
nonclinical studies, expert opinions and conference summaries. All the studies coming from 
the same center were considered and analyzed, due to the possible overlapping of clinical 
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cases reported across the studies. Letters and case reports were also not excluded a priori for 
the analysis, due to the paucity of reported cases in the literature.  
Study Selection 
A total of 307 results were observed. Two more papers were added to the research through 
references. Two reviewers (QL and FM) independently screened the identified studies and 
their extracted data. In case of disagreement, the paper was discussed by all the authors. After 
the systematic screening, 27 studies were identified for the systematic review analysis 
(Figure 1).  
Quality Assessment 
Selected studies were reviewed based on the representativeness of the study population, 
comparability of cohorts, adequate assessment of outcomes, sufficient length of follow-up, 
adequacy of follow-up, and source of study funding. The quality of the papers was assessed 
using the Newcastle-Ottawa Quality Assessment Scale (NOS): studies with scores >6 were 
defined as high-quality (Table 1). [43] 
The characteristics coming from each study were collected in four different tables. The 
following features were collected in Table 2 (hypothermic experiences) and Table 3 (sub-
normothermic/normothermic experiences): first author’s name, reference number, year of 
publication, country/city, number of patients, type of perfusion protocol used, temperature of 
MP, type of donor (DCD vs deceased brain donor [DBD]), donor age, donor gender, 
percentage of graft macro-steatosis, recipient age, recipient gender, patient cause of disease, 
concomitant presence of hepatocellular cancer (HCC), and model for end-stage liver disease 
(MELD) score.  
The following characteristics were collected in Table 4 (hypothermic experiences) and Table 
5 (sub-normothermic/normothermic experiences): timing from donor aortic flush to MP start, 
duration of perfusion on the MP, value of lactates in the perfusate at the beginning and at the 
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end of perfusion, final MP flow in the hepatic artery and portal vein, post-LT transaminases 
peaks, hospital stay in days, number of graft losses/deaths, number of cases that developed 
acute kidney injury, primary non-function, and ischemic-type biliary lesions.  
RESULTS 
The selection process of the articles is explained in Figure 1. 
As for the selection process according to the PRISMA guidelines, the examined databases 
provided a total of 309 articles to screen. Forty-two of them were removed after reading titles 
and abstracts. Of the remaining 267, 240 were not considered eligible for full-text evaluation. 
Eventually, 27 articles with a total number of 173 patients were reported on clinical LT using 
MP. [11,16-41] Some articles from the same center showed partial overlapping of reported 
cases: consequently, the global number of patients for each center was extrapolated after 
careful evaluation of the reported series, typically taking into consideration the most recent 
study. Until now, 14 LT centers have reported at least one case of clinical LT using a MP: 
New York (n=51), Zurich (n=31), Cambridge (n=14), Groningen (n=10), Toronto (n=10), 
Edmonton (n=9), Milan (n=6), Birmingham (n=6), Hessen (n=6), Turin (n=4), Pisa (n=3), 
Palermo (n=1), London (n=1) and Guangzhou (n=1). A multicenter study from the United 
Kingdom was also reported (n=20). All the cases except one were performed in Western 
countries, with 102 and 70 cases carried out in Europe and North America, respectively.  
As for the quality of the reported studies, ten and five studies were only case reports or case 
series, respectively. Thus, a NOS value was correctly established only in twelve cases: the 
overall quality of these cohort studies was globally high, with a NOS overpassing the cut-off 
of 6 in all the cases (median value=8) (Table 1).  
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A great inhomogeneity was observed among the 27 studies included in the final analysis. For 
example, normothermic machine perfusion (NMP) was performed in 65 (37.6%) cases, 
controlled oxygenated rewarming (COR) in 6 (3.4%), and different types of hypothermic 
machine perfusion (HMP) in the remaining 102 (59.0%).  
In detail, HMP was applied in 53 cases, hypothermic oxygenated perfusion (HOPE) in 31 
cases, dual hypothermic oxygenated perfusion (DHOPE) in 14 patients, and normothermic 
regional perfusion (NRP) followed by HMP in 4 cases. 
Variability was also observed in regards to the type of donor: 105 (60.7%) DBD and 68 
(39.3%) DCD were considered eligible for donation. Among the DCD donors, only 4 
uncontrolled cases (all receiving  NPR+HMP) were reported (Tables 2 and 3). Moreover, a 
total of 58 (33.5%) cases were reported in whom a liver previously refused for LT by other 
centers was initially treated with MP and then successfully transplanted. [17,18,28-31,35-38] 
Time elapsed from donor aortic perfusion to the beginning of machine perfusion varied 
widely among the different experiences, with a great span ranging from a minimum of 1.2 to 
a maximum of 14.5 hours. Such a discrepancy depended mainly on whether the used MP was 
portable or not and by the fact that some of the perfused grafts were previously discharged by 
other transplant centers, resulting in long cold storage. It must be underlined that this span 
ranging was particularly evident in HMP series because in most of them non-portable devices 
were used. Also, duration of perfusion was different in the reported series, with a range of 
1.5-18.5 hours.  
In case of NMP, lactates, when recorded, tended to decrease from an initial value ranging 
5.5-13.9 mmol/L to a final value ranging 0.03-2.8 mmol/L. Similarly, final portal and hepatic 
artery flows increased consistently during perfusion, reaching top values of 1.3 L/min and 
478 mL/min, respectively. In case of COR or HMP, a smaller number of functional aspects 
was available.    
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Post-LT transaminases peaks were not reported homogeneously among the different series, 
with only a few studies reporting both ALT and AST peak values.  
Overall results were excellent, although follow-up times were generally short. The shorter 
hospital stay was of only 5 days. Only two (1.2%) cases of primary non-function (PNF) were 
documented. Acute kidney injury was observed in 17 (9.8%) patients. Seven (4.0%) cases of 
ischemic-type biliary lesions (ITBL) were reported. The overall incidence of graft losses was 
of 12 (6.9%) cases; in one case a successful re-transplantation was performed (Tables 4 and 
5). 
Considering patients with at least 6 months of follow-up (n=154), the overall number of 
reported graft losses was of 12/154 (7.8%) cases. PNF and ITBL cases were 2/154 (1.3%) 
and 7/154 (4.5%), respectively (Tables 4 and 5).  
A separate analysis performed on high-quality papers with a NOS ≥6 (12 articles; n=167) did 
not provide homogeneous data either. When sub-normothermic and NMP were used, post-LT 
transaminases ranges were 152-4991 and 84-9200 IU/L for ALT and AST values, 
respectively, while, with HMP, they were 689->3000 and 966-3547 IU/L, respectively. In 
these well-selected series, the number of reported graft losses was of 12/167 (7.2%) cases. 
PNF and ITBL cases were 2/167 (1.2%) and 7/167 (4.2%), respectively (Tables 4 and 5). 
Another separate analysis only looking at the livers previously discarded by other centers was 
performed. In the subgroup of 57 initially declined livers in which enough information on the 
follow-up details was reported, a total of 7/57 (12.3%) graft losses was observed. It is 
interesting to observe that this percentage was superior respect to the one observed in the 
cases in which the MP was performed for testing its safety (5/115, 4.3%; p=0.11). 
Interestingly enough, the two cases of PNF both happened in the group of initially discarded 
livers (2/57, 3.5%; p=0.11). Also, ITBL rates were higher in the initially declined grafts (6/57 
vs. 1/115, 10.5 vs. 0.9%; p=0.006).  
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DISCUSSION 
The decision whether to use or discard a marginal graft for LT is a recurring dilemma for 
transplant professionals: indeed, the paucity of available grafts translates into an increased 
risk of patients dying while awaiting a transplant. [44,45] Moral issues may arise when 
deciding whom to allocate a graft to, potentially favoring a patient while harming another on 
the same waiting list. [46] Eastern LT centers have partly overcome such an impasse 
adopting a policy focused on living donation. [47] Conversely in Western countries, where a 
living donation has plateaued around a marginal role, the only solution is to expand the pool 
of available grafts from deceased donors. In this specific setting, there is growing enthusiasm 
around MPs which could lead to a revolution in liver grafts preservation and viability, 
although some concerns still exist on the systematic use of the various machines which have 
been released on the market.  
Aside from economic considerations, [48] it is strikingly evident there is great heterogeneity 
in literature around MP. Consequently, it is not possible to come to conclusions when 
commenting on selectors of graft quality from machine perfused livers.  
The majority of the studies published so far are only small case series or Phase I trials aiming 
at assessing the feasibility and safety of MP compared to cold storage. [21] This helps explain 
the excellent results observed regarding post-LT clinical course: perhaps, some of the grafts 
transplanted after MP would have also been adequate for LT with standard cold storage 
preservation. However, it is of interest to underline that when MP strategies were used in case 
of initially declined livers, the results were inferior, clearly demonstrating that the expansion 
of the routine graft selection criteria should be done cautiously also using this technology  
No clinical studies exist comparing NMP and HMP, making it not possible to suggest the 
superiority of one approach over the other.  
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NMP is conceptually very attractive, particularly in consideration of the high number of 
parameters that could be monitored during perfusion. [49] Actually, the Birmingham Group 
successfully transplanted five out of six livers declined by other centers showing maintained 
function during NMP. [29] A similar experience was reported in twelve cases by the 
Cambridge Group. [37] However, NMP requires more significant management expertise 
compared to an HMP approach. As an exemplification, two grafts were lost during NMP vs. 
no case with HMP. In detail, one graft was not homogeneously perfused due to the presence 
of an aberrant right hepatic artery which had not been reconstructed before the start of 
normothermic perfusion, [29] and the other one due to portal vein torsion during perfusion. 
[24], in both cases, the reason for discarding the livers was more related to technical 
problems than to graft quality.  
High expectations exist on the future role of NMP in the specific setting of liver steatosis, 
with the intent to develop “defatting” protocols, but no clinical studies on humans exist until 
now, something that leave this ground of research completely unexplored.   
Graft evaluation during HMP is far more difficult due to the slower metabolism of liver cells, 
with a smaller number of biomarkers and parameters which may be tested during perfusion. 
Moreover, short-term HMP is charged by a further reduced evaluation capability. However, 
yet in case of hypothermia, a variety of parameters may be detected in the perfusion fluid 
aimed at assessing the quality of the graft. [50] Of note, approximately 2/3 of all the 
experiences reported worldwide are based on a hypothermic approach.  
If it is not sufficiently clear how to select organs during normo- or hypothermic perfusion, it 
looks easier to decide which graft to perfuse. A recent review from Dutkowski et al. nicely 
stratified liver grafts concerning different risk categories, suggesting the best preservation 
strategy for each class. For example, standard DBD and DCD liver grafts can be routinely 
well preserved only with cold storage. On the opposite, grafts presenting different 
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combinations of long ischemia time, advanced donor age, type of donor and severe steatosis 
may benefit from treatment with MP. [51] 
This condition is especially true in DCDs, in which livers are often turned down even before 
deciding to go on a MP, particularly in case of uncontrolled DCD donors. For example, in a 
study from De Carlis et al., livers were declined while the donor was maintained on NRP and 
the liver showed poor perfusion and severe fibrosis at biopsy. [25] Such an approach is very 
well established in previous experiences from Spain where uncontrolled DCD donation was 
pioneered. [52] 
A recent score calculated on 1,153 DCD from the UK identified three risk classes of post-LT 
poor function and death: low risk (0-5 points), high risk (6-10 points) and futile (>10 points). 
[53] It should be intriguing to speculate that extended and even overextended DCD cases can 
be safely used after their perfusion. [51] A recent experience from the Zurich Group explores 
this specific field, reporting the use of HMP in five DCD cases with 20-40% macro-steatosis, 
and showing a 1-year patient survival of 100% respect to a historical group preserved with 
cold storage reporting only 42% of survival. [11]    
Focusing on the extension of the preservation time, three cases from Milan and Cambridge 
reached a global time from donor aortic flush to end of machine perfusion of 18.3, 18.8 and 
20.0 hours, respectively. [27,36] Being a record in this topic, the case described by Watson et 
al. was preserved for stunning 26 hours from donor cross-clamp to recipient declamping! [36] 
Indeed, the use of MP approximately tripled the cold ischemia times typically accepted for 
DBD (8 hours) and DCD donors (7 hours). [54] There is no doubt that the opportunity to 
keep the grafts perfused for a long time represents another fascinating aspect. In spite of that,  
additional studies are needed to better define the lower and upper limits of perfusion 
extension.   
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Lastly, clear end-points should be set up when using MPs, particularly in the context of 
clinical studies. Not only graft and patient survivals, but also the variables which are known 
to influence the long-term outcomes (ITBL, transaminases peaks and early allograft 
dysfunction, to name a few) should be looked at in those studies that aim to build evidence 
around the topic of MP. [55] Several randomized control trials are underway to investigate 
the role of MP, either hypo- and normothermic, in LT. [56-59] 
CONCLUSIONS 
Until now, no exhaustive study exists that address the role of perfusion machines in selecting 
liver grafts available for transplantation. All the published studies mainly focused on the 
feasibility and safety of this new technology. Further research investigating the selection 
process of marginal donors is undoubtedly required. Large prospective studies focused on 
secondary end-points such as reduction of biliary lesions and graft dysfunction rates are 
awaited. However, the future broader potentials of this technology are high, especially in the 
case of NMP, heralding the start of a new era in the setting of organ preservation for 
transplantation. 
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FIGURES 
 
Figure 1. PRISMA flowchart of the literature search and study selection.  
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